Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 sirna in human renal cell carcinomas

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2713-2719

  Sakurai, Yu ^a   Hatakeyama, Hiroto ^a   Akita, Hidetaka ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

cell cycle; combination therapy; doxorubicin; EPR effect; liposomes; renal cell carcinomas; siRNA

Indexed keywords

CATIONIC LIPID YSK05; DOXORUBICIN; LIPOSOME; NANOCARRIER; POLO LIKE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY DEVICE; DRUG EFFICACY; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; LIPOSOMAL DELIVERY; MOUSE; MULTIFUNCTIONAL ENVELOPE TYPE NANODEVICE; NANODEVICE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, RENAL CELL; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; MALE; METABOLISM; NANOTECHNOLOGY; PHENOTYPE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL CYCLE PROTEINS; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NANOTECHNOLOGY; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING;

EID: 84905444179     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500245z     Document Type: Article

References (29)

1. Pal, S. K.; Williams, S.; Josephson, D. Y.; Carmichael, C.; Vogelzang, N. J.; Quinn, D. I. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Mol. Cancer Ther. 2012, 11 (3) 526-37
2. Biswas, S.; Eisen, T. Immunotherapeutic strategies in kidney cancer - when TKIs are not enough Nat. Rev. Clin. Oncol. 2009, 6 (8) 478-87
3. Mizutani, Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma Int. J. Urol. 2009, 16 (5) 444-8
4. Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics Nat. Mater. 2013, 12 (11) 967-77
5. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discovery 2009, 8 (2) 129-38
6. Hatakeyama, H.; Akita, H.; Harashima, H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Delivery Rev. 2011, 63 (3) 152-60
7. Kogure, K.; Akita, H.; Yamada, Y.; Harashima, H. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system Adv. Drug Delivery Rev. 2008, 60 (4-5) 559-71
8. Sakurai, Y.; Hatakeyama, H.; Sato, Y.; Hyodo, M.; Akita, H.; Ohga, N.; Hida, K.; Harashima, H. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system J. Controlled Release 2013, 173C, 110-8
9. Sakurai, Y.; Hatakeyama, H.; Sato, Y.; Hyodo, M.; Akita, H.; Harashima, H. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system Mol. Ther. 2013, 21 (6) 1195-203
10. Sato, Y.; Hatakeyama, H.; Sakurai, Y.; Hyodo, M.; Akita, H.; Harashima, H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo J. Controlled Release 2012, 163 (3) 267-76
11. Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat. Rev. Drug Discovery 2010, 9 (8) 643-60
12. Strebhardt, K.; Ullrich, A. Targeting polo-like kinase 1 for cancer therapy Nat. Rev. Cancer 2006, 6 (4) 321-30
13. Wolgemuth, D. J. Function of cyclins in regulating the mitotic and meiotic cell cycles in male germ cells Cell Cycle 2008, 7 (22) 3509-13
14. Ding, Y.; Huang, D.; Zhang, Z.; Smith, J.; Petillo, D.; Looyenga, B. D.; Feenstra, K.; Mackeigan, J. P.; Furge, K. A.; Teh, B. T. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets Cancer Res. 2011, 71 (15) 5225-34
15. Hu, K.; Law, J. H.; Fotovati, A.; Dunn, S. E. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells Breast Cancer Res. 2012, 14 (1) R22
16. Tyagi, S.; Bhui, K.; Singh, R.; Singh, M.; Raisuddin, S.; Shukla, Y. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73alpha in p53 mutant human epidermoid squamous carcinoma cells Biochem. Pharmacol. 2010, 80 (9) 1326-34
17. Rodel, F.; Keppner, S.; Capalbo, G.; Bashary, R.; Kaufmann, M.; Rodel, C.; Strebhardt, K.; Spankuch, B. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer Am. J. Pathol. 2010, 177 (2) 918-29
18. Spankuch, B.; Kurunci-Csacsko, E.; Kaufmann, M.; Strebhardt, K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs Oncogene 2007, 26 (39) 5793-807
19. Ling, Y. H.; el-Naggar, A. K.; Priebe, W.; Perez-Soler, R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells Mol. Pharmacol. 1996, 49 (5) 832-41
20. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem. Pharmacol. 1999, 57 (7) 727-41
21. ODonovan, D. S.; MacFhearraigh, S.; Whitfield, J.; Swigart, L. B.; Evan, G. I.; Mc Gee, M. M. Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death Cell Death Dis. 2013, 4, e468
22. Fu, Z.; Malureanu, L.; Huang, J.; Wang, W.; Li, H.; van Deursen, J. M.; Tindall, D. J.; Chen, J. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression Nat. Cell Biol. 2008, 10 (9) 1076-82
23. Smith, L.; Watson, M. B.; OKane, S. L.; Drew, P. J.; Lind, M. J.; Cawkwell, L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays Mol. Cancer Ther. 2006, 5 (8) 2115-20
24. Xue, Y. J.; Xiao, R. H.; Long, D. Z.; Zou, X. F.; Wang, X. N.; Zhang, G. X.; Yuan, Y. H.; Wu, G. Q.; Yang, J.; Wu, Y. T.; Xu, H.; Liu, F. L.; Liu, M. Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma J. Transl. Med. 2012, 10, 200
25. Kedinger, V.; Meulle, A.; Zounib, O.; Bonnet, M. E.; Gossart, J. B.; Benoit, E.; Messmer, M.; Shankaranarayanan, P.; Behr, J. P.; Erbacher, P.; Bolcato-Bellemin, A. L. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases BMC Cancer 2013, 13, 338
26. Mui, B. L.; Tam, Y. K.; Jayaraman, M.; Ansell, S. M.; Du, X.; Tam, Y. Y.; Lin, P. J.; Chen, S.; Narayanannair, J. K.; Rajeev, K. G.; Manoharan, M.; Akinc, A.; Maier, M. A.; Cullis, P.; Madden, T. D.; Hope, M. J. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles Mol. Ther.- Nucleic Acids 2013, 2, e139
27. Robbins, M.; Judge, A.; MacLachlan, I. siRNA and innate immunity Oligonucleotides 2009, 19 (2) 89-102
28. Xie, S.; Xie, B.; Lee, M. Y.; Dai, W. Regulation of cell cycle checkpoints by polo-like kinases Oncogene 2005, 24 (2) 277-86
29. Cogswell, J. P.; Brown, C. E.; Bisi, J. E.; Neill, S. D. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function Cell Growth Differ. 2000, 11 (12) 615-23